Bridgewater's Amneal Pharmaceuticals, a global pharmaceutical company, announced that it has signed an exclusive license agreement for IPX203 in the European Union, United Kingdom and Switzerland with Italy's Zambon Biotech SA, part of the Zambon
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral gene therapies with minimally-invasive delivery technology, launches with seed finance from Pureos Bioventures and ND Capital.
Virtual Incision, a company in the cultivate (MD) portfolio, has received marketing authorization from the US FDA for the MIRA Surgical System (MIRA).
Commissioner Abhimanyu Kale of the Maharashtra Food and Drug Administration (FDA) led a raid on Mumbai-based Raj Products' premises to tackle illicit activities in the cosmetics industry.
AbbVie Inc. and OSE Immunotherapeutics SA, a clinical-stage immunotherapy company, announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in pre-clinical development.
Roche Pharma India reported the launch of its blockbuster advancement drug, Ocrevus (ocrelizumab), for the treatment of multiple sclerosis (MS), growing its nervous system science portfolio to take special care of neglected needs of various...
Bitterroot Bio, an innovator in imaginative medicines for cardiovascular ailments, and Biotheus, a trailblazer in monoclonal and multi-explicit immunizer configuration, reported a long term research coordinated agreement. This alliance will...
Eli Lilly anticipates to introduce its obesity drug tirzepatide in India as soon as the following year, David Ricks, the U.S. drugmaker's President added. "We're open to any way to reach more patients as long as it makes sense for the company...
Japan's Takeda Drug is communicating with Indian controllers to make its dengue vaccine accessible in the country, the drugmaker's worldwide head of immunizations, Gary Dubin added. "We are in talks with regulators...
Bristol Myers Squibb has established a new facility in Hyderabad. The new global site will expand the company's drug development, IT, and digital capabilities and is expected to employ more than 1,500 people.
, CDSCO.jpg)
